- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00941135
Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab
September 28, 2011 updated by: Fundacion Miguel Servet
Phase II Study of TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab "Boost Concomitant" With Cetuximab in Patients With Local Advanced Larynx/Hypolarynx Carcinoma
To evaluate the progression free time in patients with completed or partial response > 30% evaluated over primary tumour (damage T and N) after induction TPF (Docetaxel, Cisplatin, 5-FU) treated with RT + Cetuximab over 2 years.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
70
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Madrid, Spain, 28040
- Fundacion Jimenez Diaz
-
-
Andalucía
-
Malaga, Andalucía, Spain, 29010
- Hospital Carlos Haya
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Clinica Universitaria de Navarra
-
Pamplona, Navarra, Spain, 31008
- Hospital de Navarra
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient informed consent must be signed before to start the study.
- Age between 18 to 70 years.
- Performance Status 0-1 according to ECOG scale at the moment of inclusion.
- Life expectancy >3 months.
- Confirmed anatomopathologic diagnosis of local advance scaly larynx or hypolarynx carcinoma III or IV stage without evidence of distance metastasis, which surgery involve a total laryngectomy.
- T3, T4A, T4B or T2 not candidate to a partial laryngectomy. In case of T2 of both locations it will be required III or IVA stage.
- Patients in medical conditions to receive neoadjuvant treatment with TPF followed by hyperfractionated radiotherapy combined with cetuximab.
- Presence of a injury measurable with RECIST criteria.
- Neutrophils > or = 1500/mm3, platelets > or = 150.000/mm3 and haemoglobin > or =10 g/dL.
- Renal Function appropriate
- Hepatic Function appropriate
- Serum Calcium tight to albumine < or = 1,25 x upper normal limit (UNL).
- Nutritional status appropriate: weight loss < 20% and albumine > or = 35 g/L.
- Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
Exclusion Criteria:
- Metastatic disease.
- Surgical treatment, radiotherapy and/or previous chemotherapy.
- Another tumour locations in head and neck area different from larynx or hypo larynx.
- Another stages different from III or IVa without distant metastasis and resectable disease.
- Another previous scaly carcinoma
- Diagnosis of another neoplasia in last 5 years, except cervix carcinoma in situ and/or basocellular cutaneous carcinoma adequately treated.
- Active infection treated by ATB IV, including active tuberculosis and VIH.
- Hypertension not controled defined as systolic > or = 180 mm Hg and/or diastolic > or =130 mm Hg at rest.
- Pregnant/lactating women.
- Systemic immune treatment, chronic and concomitant, or cancer hormone treatment.
- Another antineoplastics concomitant treatments.
- Coronary artery disease or history of heart attack in the last 12 months or high risk of arrythmia uncontrolled or cardiac insufficiency uncontrolled.
- EPOC that required more than 3 hospitalizations in the last 12 months.
- Active ulcus not controled.
- Psychiatric illness/social situations that would limit compliance with study requirements
- Drug abuse (except alcohol abuse)
- Knowledge of Allergic to study treatment.
- Previous treatment with Monoclonal antibodies.
- Any experimental treatment in the previous 30 days to start the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate progression-free time in patients with complete or partial response >30% evaluated over primary tumour(T and N) after TPF induction treated with RT + Cetuximab.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fernando Arias, MD, Hospital de Navarra
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2009
Primary Completion (Anticipated)
May 1, 2013
Study Completion (Anticipated)
May 1, 2013
Study Registration Dates
First Submitted
July 15, 2009
First Submitted That Met QC Criteria
July 16, 2009
First Posted (Estimate)
July 17, 2009
Study Record Updates
Last Update Posted (Estimate)
September 29, 2011
Last Update Submitted That Met QC Criteria
September 28, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Otorhinolaryngologic Diseases
- Laryngeal Diseases
- Laryngeal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Immunological
- Docetaxel
- Cetuximab
Other Study ID Numbers
- HN2008
- EudraCT number: 2008-003365-29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laryngeal Neoplasms
-
Washington University School of MedicineWithdrawnLaryngeal Neoplasm | Laryngeal Dysplasia
-
Centre Hospitalier Universitaire de NīmesCompleted
-
University Hospital OstravaRecruitingLaryngeal Disease | Laryngeal Lesions | Hypopharyngeal Lesions | Suspected Laryngeal Cancer | Suspected Hypopharyngeal Cancer | Proven Laryngeal Cancer | Proven Hypopharyngeal CancerCzechia
-
Thomas Jefferson UniversityCompletedHead and Neck Carcinoma | Lung Carcinoma | Oral Cavity Carcinoma | Paranasal Sinus Carcinoma | Stage III Laryngeal Cancer AJCC v8 | Stage IV Laryngeal Cancer AJCC v8 | Hypopharyngeal Carcinoma | Laryngeal Carcinoma | Stage IVA Laryngeal Cancer AJCC v8 | Stage IVB Laryngeal Cancer AJCC v8 | Stage IVC Laryngeal... and other conditionsUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownRecurrent Laryngeal CancerChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage III Laryngeal Cancer AJCC v8 | Laryngeal Squamous Cell Carcinoma | Stage II Laryngeal Cancer AJCC v8United States
-
The Netherlands Cancer InstituteAstraZenecaActive, not recruitingHead and Neck Neoplasms | Carcinoma, Squamous Cell | Laryngeal Cancer Stage II | Laryngeal Cancer Stage IIINetherlands
-
University of Michigan Rogel Cancer CenterCompletedLaryngeal CancerUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedRecurrent Laryngeal CancerChina
-
Daping Hospital and the Research Institute of Surgery...Recruiting
Clinical Trials on Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab
-
Associazione Volontari Pazienti OncologiciMario Negri Institute for Pharmacological ResearchCompletedHead and Neck Squamous Cell CarcinomaItaly
-
Austrian South Oncology GroupChange of sponsor 2008: new sponsor AGMTCompleted
-
Hong Kong Nasopharyngeal Cancer Study Group LimitedSanofi; The University of Hong Kong; Merck Sharp & Dohme LLC; Roche Pharma AGCompleted
-
First Affiliated Hospital of Zhejiang UniversityRecruitingSquamous Cell Carcinoma of Head and NeckChina
-
Yonsei UniversityCompleted
-
Gruppo Oncologico del Nord-OvestUnknownSquamous Cell Carcinoma of the Head and NeckItaly
-
Institute of Oncology LjubljanaCompletedHead and Neck CancerSlovenia
-
Sun Yat-sen UniversityShanghai Weike Bioscience Co., Ltd.Not yet recruitingNasopharyngeal Carcinoma | TNF | Chemo-radiotherapy